The semaglutide and tirzepatide trials changed that expectation: Semaglutide 2.4 mg once weekly produced average weight loss around 15% at ~68 weeks in adults without diabetes, with a substantial fraction of participants losing 1520% of baseline weight
The whole point of a sleep-support peptide is that its window of action overlaps the hours you are actually asleep, which means the injection belongs at the end of your evening, after the last screen, after teeth, right as you sit down on the mattress
Sensitivity landmark analyses stratified by timeframe of semaglutide initiation Given that semaglutide was initially approved for type 2 diabetes, with initial obesity approval in 2021, it is possible that inclusion of non-diabetic patients could introduce indication bias in the previously described analyses, as non-diabetic patients enrolled before 2021 likely represent off-label use and may differ systematically from those treated after approval
think vitamins or general health supplements
Among other symptoms, pellagra is characterized by dementia